Q3 beat management’s expectations; guidance suspended; EQT deal in focus
09/11/26 -"Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US immigration testing left QuantiFERON sales flat, ..."
Pages
70
Language
English
Published on
09/11/26
You may also be interested by these reports :
09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...
06/11/26
In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms ...
06/11/26
S&N reported Q3 26 revenue of $1,551m (+3.4% organic), in line with consensus. Sports Medicine & ENT led (+7.9%), but continued weakness in US Knees ...
05/11/26
Siemens Healthineers’ Q4 profitability declined and was below market expectations. 2027 guidance also fell short of expectations. We will lower our ...